US equities
|
SPCX
$167.33
▲+5.27%
NVDA
$237.07
▲+1.33%
MU
$1,066.71
▼-0.76%
TSLA
$375.96
▲+1.45%
MSFT
$525.82
▲+1.60%
INTC
$116.97
▼-1.97%
SNDK
$1,721.51
▲+0.09%
META
$742.09
▲+1.92%
SPCX
$167.33
▲+5.27%
NVDA
$237.07
▲+1.33%
MU
$1,066.71
▼-0.76%
TSLA
$375.96
▲+1.45%
MSFT
$525.82
▲+1.60%
INTC
$116.97
▼-1.97%
SNDK
$1,721.51
▲+0.09%
META
$742.09
▲+1.92%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Instil Bio, Inc.
(NQ:
TIL
)
7.220
UNCHANGED
Delayed Quote
Updated: 10:29 AM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Instil Bio, Inc.
< Previous
1
2
3
4
5
6
Next >
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
February 03, 2026
From
Pomerantz LLP
Via
GlobeNewswire
CarMax Stock Down 47% This Past Year, But One Fund Is Betting $6 Million on a Turnaround
↗
February 03, 2026
CarMax runs a nationwide network of used car stores and digital channels, offering multi-channel sales and financing to U.S. consumers.
Via
The Motley Fool
Topics
Regulatory Compliance
Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter.
↗
February 03, 2026
This clinical-stage biotech develops therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition.
Via
The Motley Fool
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
January 27, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
January 20, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
January 13, 2026
From
Pomerantz LLP
Via
GlobeNewswire
On Thursday, there are stocks with unusual volume. Let's take a look.
↗
January 08, 2026
Via
Chartmill
Unusual volume stocks in Wednesday's session
↗
January 07, 2026
Via
Chartmill
Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)
September 10, 2025
From
Instil Bio
Via
GlobeNewswire
Instil Bio Posts Wider Loss in Q2
↗
August 13, 2025
Via
The Motley Fool
Topics
Intellectual Property
Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 13, 2025
From
Instil Bio
Via
GlobeNewswire
ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China
July 31, 2025
From
Instil Bio
Via
GlobeNewswire
Here are the top movers in Monday's session.
↗
July 07, 2025
Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session.
Via
Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
July 02, 2025
Via
Benzinga
Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors
July 02, 2025
From
Instil Bio
Via
GlobeNewswire
Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program
June 11, 2025
From
Instil Bio
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
↗
June 02, 2025
Via
Benzinga
These stocks are moving in today's after hours session
↗
June 02, 2025
Discover the top movers in Monday's after-hours session and stay informed about the post-market dynamics.
Via
Chartmill
These stocks that are showing activity before the opening bell on Monday.
↗
June 02, 2025
Let's have a look at what is happening on the US markets before the opening bell on Monday. Below you can find the top gainers and losers in today's pre-market session.
Via
Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
June 02, 2025
Via
Benzinga
Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer
June 02, 2025
From
Instil Bio
Via
GlobeNewswire
Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference
May 30, 2025
From
Instil Bio
Via
GlobeNewswire
Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago
May 23, 2025
From
Instil Bio
Via
GlobeNewswire
Keep an eye on the top gainers and losers in Thursday's session.
↗
May 22, 2025
Stay up-to-date with the latest market trends one hour before the close of the markets on Thursday. Explore the top gainers and losers during today's session in our detailed report.
Via
Chartmill
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
May 22, 2025
Via
Benzinga
These stocks are moving in today's session
↗
May 22, 2025
Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.
Via
Chartmill
Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated
May 22, 2025
From
Instil Bio
Via
GlobeNewswire
What's going on in today's pre-market session
↗
May 20, 2025
Wondering what's happening in Tuesday's pre-market session? Find an overview in this article.
Via
Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
May 20, 2025
Via
Benzinga
Why Pegasystems Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket
↗
May 20, 2025
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
